These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 4012666)

  • 1. [Side effects of azathioprine (Imurel). Apropos of 313 patients treated for multiple sclerosis. Review of the literature].
    Ventre JJ; Guillot M; Confavreux C; Evreux JC; Aimard G
    Therapie; 1985; 40(3):195-202. PubMed ID: 4012666
    [No Abstract]   [Full Text] [Related]  

  • 2. [Prolonged treatment of multiple sclerosis with average doses of azathioprine. An evaluation of 15 years' experience].
    Lhermitte F; Marteau R; Roullet E; de Saxcé H; Loridan M
    Rev Neurol (Paris); 1984; 140(10):553-8. PubMed ID: 6438761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Preliminary results of imurek treatment of multiple sclerosis].
    Müller J; Kreiner R; Sauermann W
    Psychiatr Neurol Med Psychol (Leipz); 1976 Dec; 28(12):755-61. PubMed ID: 1019278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Immunosuppressive therapy of multiple sclerosis using cyclosporin A and azathioprine. Long-term effects, risks, proton spin tomography and immunological findings].
    Kappos L
    Schriftenr Neurol; 1990; 32():1-200. PubMed ID: 2200108
    [No Abstract]   [Full Text] [Related]  

  • 5. [Efficacy and tolerance of cyclosporin A in the treatment of multiple sclerosis].
    Schluep M; Steck AJ; Despland PA; Regli F; Ochsner F; Berrut E; Gauthier G
    Schweiz Rundsch Med Prax; 1991 Jun; 80(24):670-2. PubMed ID: 2068440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Study of 213 cases of multiple sclerosis treated with azathioprine from 1967- to 1982].
    Aimard G; Confavreux C; Ventre JJ; Guillot M; Devic M
    Rev Neurol (Paris); 1983; 139(8-9):509-13. PubMed ID: 6648202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Long-term immunosuppression in multiple sclerosis: evaluation of treatments begun before 1972].
    Sabouraud O; Oger J; Darcel F; Madigand M; Merienne M
    Rev Neurol (Paris); 1984; 140(2):125-30. PubMed ID: 6710012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Further experiences with the Imurek treatment in multiple sclerosis].
    Müller J; Sauermann W; Kreiner R
    Psychiatr Neurol Med Psychol (Leipz); 1981 Sep; 33(9):527-31. PubMed ID: 7302005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. British Association of Dermatologists' guidelines for the safe and effective prescribing of azathioprine 2011.
    Meggitt SJ; Anstey AV; Mohd Mustapa MF; Reynolds NJ; Wakelin S
    Br J Dermatol; 2011 Oct; 165(4):711-34. PubMed ID: 21950502
    [No Abstract]   [Full Text] [Related]  

  • 10. [Immunosuppressive treatment in multiple sclerosis].
    Minderhoud JM; Prange AJ; Luijckx GJ
    Ned Tijdschr Geneeskd; 1987 May; 131(22):966-7. PubMed ID: 3299110
    [No Abstract]   [Full Text] [Related]  

  • 11. [Intrahepatic cholestasis, an allergic reaction in azathioprine therapy?].
    Haas J; Patzold U; Stamm T
    Dtsch Med Wochenschr; 1978 Oct; 103(40):1576-7. PubMed ID: 699768
    [No Abstract]   [Full Text] [Related]  

  • 12. [Multiple sclerosis--current status of therapy].
    Reichel D; Kölmel HW
    Z Arztl Fortbild (Jena); 1995 May; 89(2):151-8. PubMed ID: 7610682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Nonsteroidal anti-inflammatory agents in pediatrics (2)].
    Louis JJ
    Pediatrie; 1984 Jun; 39(4):295-313. PubMed ID: 6390335
    [No Abstract]   [Full Text] [Related]  

  • 14. [Treatment of multiple sclerosis with azathioprine (Imuran)].
    Ciesielski T; Burczyk-Popko I; Goralski H; Sypniewski J; Cendrowski W
    Pol Tyg Lek; 1974 Jan; 29(3):101-2. PubMed ID: 4594954
    [No Abstract]   [Full Text] [Related]  

  • 15. Azathioprine teratogenicity: review of the literature and case report.
    Williamson RA; Karp LE
    Obstet Gynecol; 1981 Aug; 58(2):247-50. PubMed ID: 7196003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis.
    Lebrun C; Debouverie M; Vermersch P; Clavelou P; Rumbach L; de Seze J; Wiertlevski S; Defer G; Gout O; Berthier F; Danzon A
    Mult Scler; 2008 Apr; 14(3):399-405. PubMed ID: 18420778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A preliminary evaluation of azathioprine (Imuran) in the treatment of multiple sclerosis.
    Tucker WG; Kapphahn KH
    Henry Ford Hosp Med J; 1969; 17(2):89-92. PubMed ID: 5783817
    [No Abstract]   [Full Text] [Related]  

  • 18. Immunosuppressive treatments in MS--side effects from azathioprine.
    Craner MJ; Zajicek JP
    J Neurol; 2001 Jul; 248(7):625-6. PubMed ID: 11518009
    [No Abstract]   [Full Text] [Related]  

  • 19. Azathioprine: a guide for the management of dermatology patients.
    Wise M; Callen JP
    Dermatol Ther; 2007; 20(4):206-15. PubMed ID: 17970886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Azathioprine teratogenicity: review of the literature and case report.
    Gebhardt DO
    Obstet Gynecol; 1983 Feb; 61(2):270. PubMed ID: 6823371
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.